Targeted Oncology
Targeted Oncology
Targeted Oncology


Targeted Oncology | Dialogues in Diagnostics
Targeted Oncology | Differential Diagnosis
Targeted Oncology | Case-Base Peer-Perspective

Top Medical News Today

Heinz Gisslinger, MD, Medical University of Vienna, discusses differences between polycythemia vera (PV) and essential thrombocythemia (ET).
Experts Debate Need for New Drugs to Treat Patients with PV and ET
Haifa Kathrin Al-Ali, MD, and Carlos Besses, MD, PhD debated the need for new drugs to treat polycythemia vera (PV) and essential thrombocythemia (ET). 
Expert Discusses Impact Eribulin, Trabectedin Have in Sarcoma
In the past 12 months, two agents have been approved for soft tissue sarcoma, both of which have demonstrated impressive outcomes in patients with specific subtypes of the rare disease.
Functional, Anatomic Imaging Compared in Sarcoma Study
A comparison of anatomic and functional imaging in the assessment of clinical outcomes in patients with Ewing sarcoma has shown that FDG-PET, assessed by PERCIST criteria, was superior in predicting clinical benefits and identifying responses, according to a study published in the Journal of Clinical Oncology.
Gaining More Benefit from Ruxolitinib for Patients With Polycythemia Vera, Other MPNs
Since its approval 5 years ago, ruxolitinib (Jakafi) continues to drastically change the treatment landscape and quality of life of patients with myeloproliferative neoplasms (MPNs), including a subset of patients with the bone marrow neoplasm, polycythemia vera (PV).
Management of ET, PV Requires 2 District Approaches
Distinguishing between polycythemia vera (PV) and essential thrombocythemia (ET) is key for the effective treatment of both diseases, said Heinz Gisslinger, MD, of the Medical University of Vienna.
View More >


Mesa Provides Tips for Treating Myelofibrosis After Ruxolitinib
Mesa Provides Tips for Treating Myelofibrosis After Ruxolitinib
Developing a treatment plan for myelofibrosis patients who fail ruxolitinib requires an understanding of both current treatment options and those that are expected to become available within the next several years.
Immunotherapy May Be Next Frontier for AML, Says Daver
Immunotherapy offers promise in acute myeloid leukemia (AML), a disease type which has not seen significant progress in many years, said Naval G. Daver, MD
Blinatumomab Receives FDA Approval for Acute Lymphoblastic Leukemia
Blinatumomab (Blincyto) has received accelerated approval from the FDA for the treatment of pediatric and adolescent patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
NDA for Neratinib in HER2-Positive Breast Cancer Accepted by FDA
A new drug application (NDA) for neratinib as an extended adjuvant therapy for patients with HER2-positive breast cancer following prior treatment with postoperative trastuzumab (Herceptin) has been accepted by the FDA
FDA Gives Niraparib Fast Track Designation for Ovarian Cancer
Niraparib has been granted a fast track designation by the FDA as a treatment for women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer